What is the ticker symbol for Mereo BioPharma?

Mereo BioPharma trades under the ticker MREO on NASDAQ.

What sector does Mereo BioPharma operate in?

Mereo BioPharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MREO in a portfolio?

PortView shows MREO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Mereo BioPharma (MREO) Stock Analysis

NASDAQHealthcareBiotechnology

$0.27-3.65%

1-year price historyRange $0.24 – $2.31

52-week range$0.27

$0.20$2.37

What Mereo BioPharma does

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.

Key metrics

Market cap

$42.55M

P/E (TTM)

-5.33

EPS (TTM)

$-0.05

Beta

0.30

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$0.31

200-day avg

$0.60

52-week high

$2.37

52-week low

$0.20

CEO

Denise Vera Scots-Knight

ETFs linked to MREO

Broad-market and Healthcare sector ETFs an investor holding Mereo BioPharma is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how MREO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze MREO in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Mereo BioPharma?: Mereo BioPharma trades under the ticker MREO on NASDAQ.
Which exchange is MREO listed on?: MREO is listed on NASDAQ.
What sector does Mereo BioPharma operate in?: Mereo BioPharma is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze MREO in a portfolio?: PortView shows MREO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.